Half dose of teprotumumab shows potential in active moderate-to-severe TED

In a poster presented at AAO 2022, researchers highlighted the first reported successful treatment of active moderate-to-severe thyroid eye disease (TED with half a dose of teprotumumab.

This case has led researchers to consider the potential benefit of reducing teprotumumab dosage to decrease the likelihood of teprotumumab-induced hearing loss.

In the case, a 64-year-old woman had TED reactivation after previously undergoing 4 infusions of teprotumumab and experiencing sensorineural hearing loss (SNHL) which resolved to baseline 6 months after therapy was discontinued.

The patient was unresponsive to IV solumedrol and orbital radiation. After progression of TED symptoms, the patient began treatment with teprotumumab at a half dose of 10 mg/kg, with frequent audiometry, and had significant improvement in proptosis, eyelid swelling, and double vision without additional hearing loss.

Reference
Phansalkar R, et al. Decrease of Teprotumumab-induced Hearing Loss with Comparable Efficacy Against TED using Dose Reduction. Poster presented at: AAO 2022.